---
title: "Daxor Files Legal Opinion Affirming Validity of Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273753444.md"
description: "Daxor (DXR) has filed a legal opinion from Foley & Lardner LLP affirming the legality of its common stock, enhancing regulatory compliance and investor confidence. The latest analyst rating for DXR is a Hold with a $13.00 price target. Spark's AI Analyst rates DXR as Neutral, citing mixed financial performance and a high P/E ratio as valuation concerns, despite a strong balance sheet and positive technical indicators."
datetime: "2026-01-26T22:13:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273753444.md)
  - [en](https://longbridge.com/en/news/273753444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273753444.md)
generator: "portal-rs"
---

# Daxor Files Legal Opinion Affirming Validity of Stock

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Daxor ( (DXR) ) has shared an update.

Daxor filed a legal opinion from Foley & Lardner LLP regarding the legality of its common stock, indicating that the company has obtained formal legal validation for the issuance or status of its shares. This filing helps reinforce regulatory compliance and may provide additional assurance to investors and other stakeholders about the legitimacy of Daxor’s common stock offering or existing equity structure.

The most recent analyst rating on (DXR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Daxor stock, see the DXR Stock Forecast page.

**Spark’s Take on DXR Stock**

According to Spark, TipRanks’ AI Analyst, DXR is a Neutral.

The score is driven primarily by mixed financial performance: a strong, low-debt balance sheet offsets volatile results and inconsistent cash flow conversion. Technicals are constructive with price above major moving averages, but momentum looks somewhat stretched. Valuation is a headwind given the high P/E and no dividend yield data.

To see Spark’s full report on DXR stock, click here. 

**More about Daxor**

**Average Trading Volume:** 5,527

**Technical Sentiment Signal:** Buy

### Related Stocks

- [DXR.US](https://longbridge.com/en/quote/DXR.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)

## Related News & Research

- [10:10 ETLRS SECURES IDE TO STUDY ITS THERMOSUIT COOLING DEVICE IN A PIVOTAL TRIAL OF ISCHEMIC STROKE PATIENTS](https://longbridge.com/en/news/277488497.md)
- [Key facts: Boston Scientific CHAMPION‑AF and HI‑PEITHO Met Endpoints](https://longbridge.com/en/news/280887013.md)
- [Embecta to Acquire Owen Mumford for Up to £150 Million; £100 Million Upfront, Milestones Through 2028](https://longbridge.com/en/news/279922998.md)
- [John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening | ABT Stock News](https://longbridge.com/en/news/280311595.md)
- [Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG](https://longbridge.com/en/news/282038882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**